menu search

Will dynavax's (dvax) growth momentum continue in 2022?

Year-over-year revenue growth for HEPLISAV-B and CpG 1018 adjuvant is expected to drive Dynavax???s (DVAX) profitability in 2022....

February 15, 2022, 12:20 pm

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Okyo pharma receives us regulatory approval to take dry disease candidate directly into a phase ii trial

OKYO Pharma Ltd said the US regulator has given it the green light to take its dry eye disease treatment directly into a phase II clinical trial. The ...

February 15, 2022, 2:36 am

Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences

AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. Get the Insi...

February 3, 2022, 2:24 pm

Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences

AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. Get the Insi...

February 3, 2022, 2:24 pm

Astrazeneca dumps off mid-stage cardiovascular drug to regio biosciences

AstraZeneca plc AZN has granted exclusive development and commercial rights to Regio Biosciences for REG-101, a cardiovascular drug. Get the Insi...

February 3, 2022, 2:24 pm

Why are biophytis shares trading higher during premarket trading?

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized pa...

February 3, 2022, 9:03 am

Why are biophytis shares trading higher during premarket trading?

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized pa...

February 3, 2022, 9:03 am

Why are biophytis shares trading higher during premarket trading?

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized pa...

February 3, 2022, 9:03 am

4 clinical catalysts on tap for relmada in 2022

RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not...

January 28, 2022, 1:06 pm

4 clinical catalysts on tap for relmada in 2022

RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not...

January 28, 2022, 1:06 pm

4 clinical catalysts on tap for relmada in 2022

RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not...

January 28, 2022, 1:06 pm

Okyo pharma confirms ok-101 timeline

OKYO Pharma Ltd confirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In commentary...

January 26, 2022, 3:53 am

Okyo pharma confirms ok-101 timeline

OKYO Pharma Ltd confirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In commentary...

January 26, 2022, 3:53 am

Okyo pharma confirms ok-101 timeline

OKYO Pharma Ltd confirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In commentary...

January 26, 2022, 3:53 am

Okyo pharma reconfirms ok-101 timeline

OKYO Pharma Ltd has reconfirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In comm...

January 26, 2022, 2:44 am

Okyo pharma reconfirms ok-101 timeline

OKYO Pharma Ltd has reconfirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In comm...

January 26, 2022, 2:44 am

Okyo pharma reconfirms ok-101 timeline

OKYO Pharma Ltd has reconfirmed the timeline for a phase II study of its lead asset OK-101, which is being developed to treat dry eye disease. In comm...

January 26, 2022, 2:44 am

Mindset pharma enters manufacturing deal with leading cdmo for next-generation psilocybin drug candidate, msp-1014

Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) announced that it has entered into a pharmaceutical manufacturing agreement with a leading contract develop...

January 25, 2022, 8:15 am


Search within

Pages Search Results: